临床应用IRESSA治疗晚期非小细胞肺癌不良反应的护理
出处
《泰山医学院学报》
CAS
2008年第11期921-922,共2页
Journal of Taishan Medical College
二级参考文献9
-
1Fukuoka M,Yano S,Giaccone G, et al.Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer[J].J Clin Oncol,2003 Jun 15,21(12):2237-2246.Epub 2003 May 14.
-
2LoRusso PM,Herbst RS,Rischin D, et al.Improvements in Quality of Life and Disease-related Symptoms in Phase I Trials of the Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Non-Small Cell Lung Cancer and Other Solid Tumors[J].Clin Cancer Res,2003 Jun,9(6):2040-2048.
-
3Schiller JH.New directions for ZD1839 in the treatment of solid tumors[J].Semin Oncol,2003 Feb,30(1 Suppl 1):49-55.
-
4Baselga J,Rischin D,Ranson M.Calvert HPhase I safety,pharmacokinetic,and pharmacodynamic trial of ZD1839,a selective oral epidermal growth factor receptor tyrosine kinase inhibitor,in patients with five selected solid tumor types[J].J Clin Oncol,2002 Nov 1,20(21):4292-4302.
-
5Lorusso PM.Phase I studies of ZD1839 in patients with eommon solid tumors[J].Semin Oncol,2003 Feb,30(1 Suppl 1):21-29.
-
6Okamoto I,Fujii K,Matsumoto M, et al.Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer[J].Lung Cancer,2003 Jun,40(3):339-342.
-
7Sirotnak FM.Studies with ZD1839 in preclinical models[J].Semin Oncol,2003 Feb,30(1 Suppl 1):12-20.
-
8Ritter CA,Arteaga CL.The epidermal growth factor receptor-tyrosine kinase:a promising therapeutic target in solid tumors[J].Semin Oncol,2003 Fed,30(1 Suppl 1):3-11.
-
9Herbst RS.Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients[J].Semin Oncol,2003 Feb,30(1 Suppl 1):30-38.
共引文献7
-
1周小平,缪景霞,李艳,高娟.ZD1839治疗晚期非小细胞肺癌毒副反应的护理[J].护理研究,2005,19(10B):2101-2102. 被引量:5
-
2赖仁胜,谢玲,申龙树,贺亚敏,朱长乐.表皮生长因子受体基因突变与非小细胞肺癌的基因靶点药物治疗[J].中华病理学杂志,2005,34(11):745-746. 被引量:1
-
3周小平,缪景霞,廖荣荣,钱敏.吉非替尼治疗晚期非小细胞肺癌不良反应的观察及护理[J].中华护理杂志,2005,40(11):834-835. 被引量:19
-
4张可,谢广茹,潘战宇.小分子酪氨酸激酶抑制剂治疗非小细胞肺癌研究进展[J].中国肿瘤临床,2006,33(2):115-118.
-
5李子明(综述),廖美琳(审校).局部晚期非小细胞肺癌治疗策略的新进展[J].中国癌症杂志,2007,17(11):897-902. 被引量:5
-
6潘志强,谭才宏.表皮生长因子受体酪氨酸激酶抑制剂治疗肺癌停药标准研究[J].临床合理用药杂志,2014,7(26):87-88.
-
7林丽雅.102例肺癌的病理分析[J].广东职业技术教育与研究,2015(6):198-199.
-
1易红梅.IRESSA治疗晚期非小细胞肺癌疗效观察及不良反应护理[J].浙江中医药大学学报,2007,31(2):225-225. 被引量:4
-
2孔秋焕,赖月容,梁敏.易瑞沙治疗一线化疗失败的非小细胞肺癌的护理[J].现代护理,2008,14(4):513-514. 被引量:1
-
3周小平,缪景霞,李艳,高娟.ZD1839治疗晚期非小细胞肺癌毒副反应的护理[J].护理研究,2005,19(10B):2101-2102. 被引量:5
-
4周常华.中药水剂治疗肺癌患者口服易瑞沙后产生皮疹的疗效观察[J].护士进修杂志,2011,26(3):283-284. 被引量:9
-
5钱芳.原发性肝癌介入治疗的全程护理体会[J].中华全科医学,2009,7(5):549-549. 被引量:5
-
6肖宇.护理干预在易瑞沙治疗肺癌致不良反应中的应用[J].齐鲁护理杂志(上旬刊),2012,18(12):76-77. 被引量:1
-
7都三平,王燕,皮细类.护理干预对宫颈癌根治术后尿潴留的影响[J].求医问药(下半月刊),2011,9(1):64-64.
-
8周峰,卞银珠,刘红旗.易瑞沙联合放化疗治疗肺癌脑转移40例[J].医药前沿,2015,5(25):32-34.
-
9张元芳.前列腺特异抗原检测与前列腺癌诊治之间关系的思考[J].继续医学教育,2006,20(11):5-7. 被引量:2
-
10吴燕.30例危重病患者行连续性肾脏替代治疗的护理[J].中国医疗前沿,2012,7(16):80-80.